AI-Designed Cancer Drug Clears Regulatory Milestone: ISM6331 Granted FDA Fast Track Designation

From an algorithm proposing a molecule to a drug candidate entering human testing and receiving an expedited regulatory designation, ISM6331 has brought “AI drug discovery” to a more testable stage. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to this pan-TEAD inhibitor for adult patients with unresectable malignant pleural mesothelioma whose disease has progressed following existing treatment.

ISM6331 targets the TEAD family of transcription factors in the Hippo signaling pathway. This pathway is involved in cell growth and tissue homeostasis; when its regulation is disrupted, it may help tumor cells proliferate and survive. Insilico Medicine describes ISM6331 as a non-covalent, small-molecule pan-TEAD inhibitor intended to disrupt abnormal tumor growth signals by inhibiting multiple TEAD proteins simultaneously.

Here, AI is not used to diagnose patients or predict clinical responses, but to assist in designing and screening compounds. According to the company, its Chemistry42 platform uses structure-guided design, followed by multiple scoring and reward mechanisms to prioritize candidate molecules, ultimately producing ISM6331 with a novel scaffold. However, there is currently insufficient publicly available information to independently assess how the platform influenced decisions at each step, how many candidates were compared, or how much time and cost it saved relative to traditional medicinal chemistry.

The clinical trial registry shows that NCT06566079 is a recruiting Phase 1, open-label, multicenter, first-in-human study divided into dose-escalation and dose-selection portions. The trial is expected to enroll 100 patients with malignant mesothelioma or other advanced, metastatic solid tumors at sites in the United States and China. It will primarily evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics, while also exploring the recommended Phase 2 dose and preliminary antitumor activity; the study is expected to be completed in February 2028.

The FDA’s Fast Track program is intended to facilitate the development of drugs for serious diseases and unmet medical needs. ISM6331 may therefore have more frequent meetings and written communications with the FDA; if it later meets the relevant criteria, it may also qualify for rolling submission, priority review, or accelerated approval. This designation does not mean that the FDA has confirmed efficacy, nor does it lower the safety and efficacy evidence thresholds required for marketing approval.

Results from the first group of participants in the human trial have been accepted for presentation at the European Society for Medical Oncology ESMO 2026 Congress and are scheduled to be presented as a rapid oral report in Madrid on October 25. Because the specific response rate, duration of response, dose-limiting toxicities, and number of participants have not yet been disclosed, it is currently possible to confirm only that ISM6331 has reached a clinical and regulatory milestone; whether an AI-designed molecule can translate into reproducible patient benefits will still need to be answered by complete human data.